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Summary The effect of adriamycin (ADM) infusion-rate on cellular ADM concentrations and on
clonogenicity of human haematopoietic cells was studied in vivo and in vitro. In patients an ADM dose of
30mgm-2 was administered as a bolus injection, or as a 4h or a 24h infusion. In vitro the effect of ADM on
clonogenic cell growth was determined after exposure during 5min, 2h and 24h of human bone marrow cells to
increasing ADM concentrations. ADM showed rapid intracellular accumulation, to levels 100-fold the plasma
concentration in vivo or the incubation medium concentration in the in vitro experiments. After a bolus
injection or 5min exposure only 10% of the cellular peak ADM was retained after elimination of the drug
from the plasma or the incubation medium. Ninety percent of the ADM was apparently 'loosely' bound.
After 4h and 24h constant-rate infusions and also after 2h and 24h incubations in vitro, the cells
accumulated ADM gradually, and the subsequent washing-out of the cellular ADM was substantially less,
most of the ADM being 'tightly' bound. Despite these different patterns of uptake and retention after in vivo
short- and long-lasting infusion of the same total dose, the 'tightly-bound' cellular ADM concentrations were
the same. Moreover, comparable cellular ADM concentrations, retained after efflux of the 'loosely-bound'
cellular ADM fraction were equally cytotoxic to normal human clonogenic cells. Short-lasting cellular peak
ADM concentrations which occur after a bolus injection or after short exposure to high ADM concentrations
are not essential for the cytotoxic effect, in contrast to the retained, 'tightly-bound' cellular ADM levels.
Adriamycin (ADM), usually given as a bolus injection, has
also been administered as a constant rate infusion for several
hours or days. Prolonged administration of anthracyclines
has the advantage of avoiding high peak plasma
concentrations (Legha et al., 1982; Speth et al., 1986) thus
reducing side-effects such as nausea, vomiting and cardio-
toxicity (Legha et al., 1982). Given as bolus injections the
cumulative ADM dose is limited to 550mgm-2, but this
dose can be safely exceeded if ADM is infused (Legha et al.,
1982; Benjamin et al., 1985). Therapeutic efficacy of
continuous infusions appeared not different from that of
bolus injections, as was observed in leukaemia (Lewis et al.,
1985) and in breast cancer treatment (Garnick et al., 1982).
No data are available regarding either the cellular ADM
levels or the cytotoxicity to clonogenic cells following the
different modes of administration. In this study plasma and
cellular ADM concentrations were monitored in plasma,
blood cells and bone marrow cells and bone marrow samples
were assayed for clonogenicity. In vivo studies were
supplemented by in vitro experiments, in which the cellular
ADM levels were measured after different exposure times to
various ADM concentrations. This approach offered the
possibility to study the effects of both short-lasting cellular
peak concentrations and long-lasting lower cellular drug
concentrations on clonogenicity.
Materials and methods
Drugs
ADM was obtained from Laboratoire Roger Bellon S.A.
(Neuilly sur Seine, France). The ADM concentrations in the
stock solutions were checked by high pressure liquid
chromatography.
ADM measurements in vivo
Patients with leukaemia in remission were treated with ADM
(30mgm-2, day 1), vincristine ( mgm-2, day 2) and
cytosine arabinoside (200mgm 2, day 1 to 7). ADM was
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administered as a bolus injection or as a continuous infusion
of 4 or 24h. Blood and bone marrow samples were drawn
into heparinized polypropylene tubes on ice for deter-
mination of plasma and cellular ADM concentrations. After
centrifugation plasma was collected and stored at -20°C
until analysis. The red cells in the pellet were lysed with
NH4C1. After centrifugation the cell pellet was resuspended
in PBS. Part of the suspension was kept on ice for flow
cytometric determination ofADM concentrations in blast cells
and part of the cell suspension was stored at -20°C for
analysis by high pressure liquid chromatography (HPLC)
(Speth et al., 1985).
In vivo measurement ofclonogenicity
In 2 patients (leukaemia in remission) clonogenicity was
determined before and 1 h after a push injection, given as
part of the maintenance treatment. In a third patient,
suffering from chronic granulocytic leukaemia, clonogenicity
was determined in blast cells taken from the peripheral blood
before and after a 4h infusion of increasing ADM dosages
of 40 to 80mgm-2 on 6 consecutive occasions.
In vitro ADM exposure
Normal bone marrow cells were used for in vitro ADM
exposure. Aspirates, obtained from cardiac surgery patients
(Dept. Cardiac Surgery, courtesy of Prof. L.K. Lacquet)
were collected in acid citrate dextrose (ACD-A, pH 7.4).
After addition of isotonic glucose phosphate (buffer) the
suspensions were centrifuged to remove plasma and fat. The
pellet was resuspended in 35ml buffer supplemented with
5% foetal calf serum (FCS), layered onto 15ml Percoll
(density 1.085 gml -1, pH 7.4, 300mOsmkg -1) and centrifuged
to remove the bulk of red cells and mature granulocytes
(De Witte et al., 1982). Cells at the interphase were washed
twice with buffer and resuspended in Dulbecco's Modified
Eagles Medium (DMEM) supplemented with 10% FCS.
In each experiment, 30ml cell suspensions at a
concentration of 105 cellsml 1 were aliquoted in 50ml
polypropylene tubes (Greiner, Niirtingen, FRG) and pre-
incubated at 37°C for 1 h. ADM was added and the
suspensions were incubated for 5min (0.2-12.5jigml-'), 2h
(0.05-5 ugml-1) or 24h (0.005-0.5 igml-1). At the end of
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the incubation the suspensions were placed on ice to stop
further drug uptake and one sample removed for ADM
assay. Subsequently the cell suspensions were diluted twice
with cold buffer (0°C) and centrifuged (900g, 0°C, 5min).
After a second wash step the pellet was resuspended in
culture medium and a second sample was taken for FCM-
analysis of cellular ADM concentrations. Part of the cell
suspension was plated in semi-solid medium to determine
clonogenic potential. Part of the cell suspension was diluted
in drug-free liquid medium, in order to investigate drug
efflux during reincubation.
Granulocyte-macrophage colonyforming cells (CFU-GM)
assay
All cultures were performed in duplicate in 35mm Petri
dishes (Costar, Cambridge, Mass, USA) as described
previously (De Witte et al., 1982). In brief, each dish
contained 2ml of a cell suspension (105cellsml-) in
DMEM supplemented with 20% FCS, 5% (v/v) colony
stimulating activity from human placental conditioned
medium as described by Verma et al. (1980) and 0.3% (w/v)
bacto agar (Difco, Detroit, Mich, USA). The cultures were
incubated at 37°C in a fully humidified atmosphere of 5%
CO2 in air. After 12 days cell aggregates consisting of 40
cells or more were scored as colonies.
Light scatter and cellularfluorescence measurement by FCM
FCM measurements were performed on a System 50 H
Cytofluorograph (Ortho Diagnostic Systems, Westwood,
MA, USA) equipped with a 5W argon laser (164-05, Spectra
Physics, Mountainview, CA, USA) exciting at 488nm with
an intensity of 0.5W. Fluorescence was measured with a
barrier filter OG550 (Melles Griot Optical Industries, Costa
Mesa, CA, USA). The combination of forward light scatter
(FLS) and perpendicular light scatter (PLS) was used to
discriminate the blast cell subpopulation from other white
cell subpopulations and cell debris (Speth et al., 1985). From
each sample at least 12 x 103 cells were analysed at a flow
rate of 1,000cellssec-1.
FLS, PLS and fluorescence per blast cell (FU/cell) were
measured in area mode, stored in list mode and analysed on
a PDP 11/34 computer (Digital Electronic Company,
Maynard, MA, USA). Blast cell ADM concentrations were
expressed in arbitrary FU/cell representing the mean
fluorescence of this cell subpopulation. All fluorescence data
presented are corrected for autofluorescence by subtracting
the blank value. As described previously, the arbitrary
fluorescence units correlated well with cellular ADM
concentrations determined by HPLC (r=0.99, n =9);
100 FU/cell appeared to correspond with -4 to 5 fg/cell,
assuming the volume of 109 cells to be 1 ml (Speth et al.,
1985).
Measurement ofplasma and cellular ADM by HPLC
The straight-phase HPLC method used was described
previously (Speth et al., 1986). In brief, 3 ml
chloroform/methanol 9: 1 (v/v) was added to 250p1 sonicated
cell suspension or 500p1 plasma, followed by 100pl Tris
buffer (I M, pH 8.8) containing daunomycin as internal
standard. After two extractions with chloroform/methanol
9: 1 (v/v), the chloroform phase was evaporated. The residue
was dissolved in 750pl chloroform/methanol, with addition
of 50 ul Tris buffer. A 500M1 sample was injected onto the
column (Lichrosorb 7Si60 column 100 x 3.0mm I.D.).
Detection was carried out with a fluorometer (i-excitation at
488nm, A-emission above 550nm) (FS 970L.S. Fluorometer,
Schoeffel Instr, Ramsey, NJ, USA). The detection limit of
ADM and adriamycinol was 1 ng. The within-day precision
of the method (n= 17) was 7.0%.
Curvefitting ofADM concentration-response curves
The ADM concentration-response curves were fitted
according to a model described by the formula:
f(x)2- 1
This function contains three dimensions: (a) represents the
maximal plating efficiency (= 100%), (b) represents the
concentration at which inhibition amounted to 70%, (c)
represents the slope of the downward leg of the curve. The
model was fitted according to the Gauss-Newton regression
procedure with the use of least square criteria (Murray,
1972).
Results
In vivo plasma and cellular ADM concentrations
The cellular and plasma ADM and plasma adriamycinol
concentrations after bolus injection or 4h or 24h infusions
are illustrated in Figure 1. Peripheral blood cell ADM
concentrations appeared to correlate well with the simul-
taneously investigated bone marrow ADM concentrations
(n=47, r=0.82). After a bolus injection of ADM
(30mgm-2) peak plasma ADM concentrations of
2405+1720ngml- l (n=9, mean+s.d.) were noted. The
plasma disappearance curve of ADM showed a biphasic
pattern with a rapid first half-life of - 4 min, followed by a
terminal half-life of -40h.
Cellular accumulation of ADM followed the plasma levels
almost simultaneously and reached peak concentrations of
5740+2100ngml-1 cells (Figure 1). The cellular ADM
disappearance curves were also biphasic. A short-lasting
rapid phase (half-life of 1I0min) was followed by a phase
with a slow disappearance rate with a half-life of -100h.
The difference between plasma and cellular ADM half-lives
resulted in cellular ADM concentrations that were 3 orders
of magnitude higher than the plasma concentrations at 24 to
48 h after administration.
When the same dose of ADM was administered as a 4h
constant-rate infusion, maximal plasma concentrations were
- 60-80ngml -1. The cellular concentrations showed peak
levels of 1100-1200ngml-1. In case of a 4h infusion the
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Figure 1 Representative plasma (0) and cellular (x) ADM and
plasma (0) adriamycinol concentration time curves after ADM
30mgm 2 administered as bolus injection (a), 4h (b) and 24h
(c) continuous infusion. Arrows indicate the administration
times. Cellular levels refer to peripheral blood cells, shown to
correlate well with bone marrow ADM concentrations (see text).
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ADM efflux from the cells at the end of the infusion was
much less extended compared with bolus injection. In the
second, slow ADM disappearance phase, the cellular and
plasma ADM curves had similar half-lives to those observed
in the case of bolus injection. Constant-rate infusion of 24h
resulted in even lower maximal plasma levels (20ngml-1)
and a slow but continuous increase of cellular ADM
concentrations during the infusion period. At the end of the
infusion hardly any loss of cellular ADM was observed.
In all three modes of drug administration 1 h after the
plasma ADM concentrations had reached negligible values,
(<I0ngml-1) almost identical cellular drug concentrations
were attained (Figure 1).
In vitro cellular ADM concentrations
Human bone marrow cells were exposed to a range of ADM
concentrations for 5min, 2h and 24h. Cellular ADM uptake
and release were measured during ADM exposure and
subsequent reincubation in drug-free medium (n= 5). Figure
2 shows an example of the cellular ADM levels after 5min,
2 h and 24h exposure to ADM concentrations of 5000, 400
and 40ngml-1 respectively. The incubation concentrations
in this example were chosen to result in similar growth-
inhibition of clonogenic cells (80%). It is seen that the
plateau concentrations (cellular ADM concentration at
reincubation) were comparable. Furthermore the time
courses of cellular ADM concentration were essentially the
same as observed after in vivo bolus injection and short- or
long-term infusion respectively (Figure 1). A rapidly attained
and high cellular ADM concentration after the short-lasting
exposure, was followed by a considerable loss (87-91%)
during the two wash steps. During the 2h and 24h exposure
a more gradual increase of cellular ADM concentrations was
followed by a less pronounced loss after the wash steps (27-
51% and 12-23% respectively, range of 5 experiments).
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clonogenicity at the end of the infusion decreased from 51%
(40mgm 2) to 30% (80mgm-2) of the pre-infusion values.
The in vitro concentration-response curves for all 3
exposure times are plotted in Figure 3 (n=5). The
concentration at which 50% inhibition of clonogenic cells
occurred (IC50) was calculated from the fitted curves. After
5min exposure the IC50 was 2.2jigml-1 ADM. Prolonged
exposure resulted in cytotoxicity at lower ADM medium
concentrations, the IC50 being 0.35 and 0.05pgml-' after
2h and 24h respectively. An even lower IC50 of
0.0056 igml-1 was achieved after continuous exposure
during 12 days culturing when ADM had been added to the
semi-solid culture medium.
Figure 4 shows the inhibition of clonogenicity as a
function of the cellular ADM concentrations, measured at
the moment of plating the cells in semi-solid medium. For
each point the s.d. ranged between 5 and 25%. The fitted
concentration-response curves did not show significant
differences.
Discussion
The first part of the in vivo cellular ADM concentration-time
curves observed after administration of 30mgm2 ADM as
bolus injection, short-lasting and long-lasting infusions
.R
16
.E
:3
C/)
Adriamycin medium concentration (,ug ml-1)
Figure 3 Inhibition of clonogenic cells at increasing ADM
concentrations for different incubation times. (+)=5min
incubation, (x )=2h incubation, (O)=24h incubation,
(Ol)=continuous exposure. The relative number of colonies is
expressed as mean percentage of two duplicate control cultures
for each incubation time (n=5). S.d. varied from 5-15%. Curves
were fitted as described in the text.
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Figure 2 Example of cellular ADM concentrations attained
after in vitro exposure of bone marrow cells during 5min to
5 jgADM ml- 1 (a), 2h to 400 ngADM ml - 1 (b) and 24h to
40ngADMml-' (c). Arrows indicate the incubation times. The
heights of the arrow indicate the medium ADM concentrations.
Cellular ADM concentrations and clonogenicity (CFU-GM)
In 2 patients clonogenicity was determined before and 1 h
after ADM 30mg m 2 push injection. Clonogenicity was
depressed from 100% (before) to 79 and 44% after ADM.
In 1 patient clonogenicity was determined on 6 consecutive
occasions before and after a 4h infusion of ADM in
increasing dosages of 40 to 80mg m 2. Inhibition of
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Figure 4 Inhibition of clonogenicity plotted against cellular
ADM concentrations expressed in fluorescence units per cell
(FU/cell) measured after ADM exposure. (+) =5min, (x ) =2h
and (O) =24h exposure. The relative number of colonies is
expressed as percentage of two duplicate control cultures for
each incubation time (n=4). Curves were fitted as described in
the text.
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appeared essentially different; after bolus injection high peak
concentrations were observed, in contrast to long-lasting
infusions, showing a gradual increase of cellular ADM.
However, the second part of the concentration-time curves,
from the moment the plasma concentrations became negli-
gible, the cellular ADM concentrations reached comparable
levels and showed similar disappearance rates.
The cellular ADM disappearance curves observed in vitro
after 5min, 2h and 24h exposure showed similar patterns as
observed in vivo after a bolus injection, a short- and long-
lasting infusion respectively. The shorter the ADM-infusion
or the ADM-exposure time in vitro the more ADM was
accumulated intracellularly in the initial phase, but also more
of the initially accumulated ADM was subsequently lost. The
net result was comparable ADM concentrations if the same
total dose was used (in vivo), called 'tightly bound' ADM in
contrast to the 'loosely-bound' ADM lost after dis-
appearance of plasma ADM. In vitro the 'tightly-bound'
ADM concentrations correlated well with the level of
inhibition of clonogenic cells. Loss of cellular ADM after
reincubation in drug free medium has been described
previously (Preisler & Raza, 1984). Although the mechanism
behind this observation is speculative, it may be explained by
a two compartment model with a fast but reversible
cytoplasmic accumulation followed by an irreversible
intercalation into DNA at a slower rate (Skovsgaard, 1978).
Both Nguyen-Ngoc et al. (1984) and Andersson et al.
(1982) have concluded from their in vitro experiments that
the cellular peak-concentrations of anthracyclines obtained
after bolus injection, produce a higher cytotoxicity than the
lower ADM concentrations after long-lasting infusions. Their
conclusions were based on the in vitro observation that the
ADM dose (product of concentration and exposure time)
had to be increased with increasing exposure time. The
results from this study indicate however that in vivo,
administration of the same dose at different infusion rates
results in comparable 'tightly-bound' cellular ADM
concentrations and comparable inhibition of clonogenic cells.
This apparent controversy has to be explained by the
translation by the above-mentioned authors of in vitro results
to the in vivo situation, ignoring the totally different
exposure conditions in the body (e.g. plasma disappearance
curves, protein binding) and in the test tube. The concept of
dose in the in vivo situation, cannot be considered equivalent
to the in vitro concentration-time product. However, in vivo
and in vitro comparisons can be made if the cellular ADM
concentrations are the same during the experiments.
Bailey-Wood et al. (1984) concluded from their in vitro
observations that the high drug concentrations present in the
plasma for short periods of time following rapid i.v. infusion
were only weakly cytotoxic and advised long-lasting
infusions and low dosages.
In this study we have shown that short-lasting exposure to
high concentrations can be just as cytotoxic as long-lasting
exposure to lower ADM concentrations, provided that
similar cellular ADM concentrations are retained after the
elimination of plasma (or medium) ADM. In clinical
practice, however, bolus injection in contrast to long-lasting
infusions causes more side-effects, such as nausea and
vomiting and increased cardiotoxicity.
Preliminary results showed that the concept of cytotoxicity
to be correlated directly to the 'tightly-bound' cellular ADM
fraction is valid for leukaemic clonogenic cells (data to be
published).
'Tightly-bound' cellular ADM levels observed after a total
dose of 30mgm 2 did not result in complete inhibition of
clonogenic cells. Also clonogenicity was not completely
depressed in the patient treated with increasing ADM
dosages up to 80mgm-2. These results indicate that the in
vivo attained 'tightly-bound' cellular ADM concentrations
are not high enough to completely kill clonogenic cells. If
these observations are also valid for leukaemic clonogenic
cells, therapeutic schemes containing anthracyclines should
be reconsidered.
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